CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma

Etan Marks, Yang Shi, Yanhua Wang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Aims: Plasmablastic plasma cell myeloma (PPCM) is a rare morphological presentation of multiple myeloma, and can resemble plasmablastic lymphoma (PBL), a human immunodeficiency virus (HIV)-related lymphoid neoplasm, morphologically and immunophenotypically. The aim of this study was to retrospectively search for factors that could help to differentiate these two entities. Methods and results: We used clinical looking glass, a data mining tool, to identify patients with a diagnosis of either PPCM or PBL with a CD117 test performed. We identified 27 cases from 16 patients in our institution with a diagnosis of either PPCM or PBL. There were 14 cases of PBL from eight patients and 13 cases of PPCM from eight patients. We found that six of eight patients with PPCM were positive for CD117, whereas no patients with PBL (0/8) showed positivity (P = 0.007 for patients). All (8/8) PPCM patients had a paraproteinaemia, whereas only two of eight PBL patients had a paraproteinaemia (P = 0.007). Lytic bone lesions were more indicative of a PPCM, with six of eight patients showing these lesions, and only one of eight PBL patients showing these lesions (P = 0.0406). HIV status was more likely to be positive in PBL patients, with six of seven patients showing positivity, and only one of five PPCM patients showing positivity (P = 0.072). Epstein–Barr virus-encoded RNA in-situ hybridization did not differentiate these two entities, with seven of eight PBL patients showing positivity, and two of five PPCM patients showing positivity (P = 0.2168). Conclusions: This study reveals that CD117 can be a useful marker to help differentiate PPCM from PBL and give the patient an appropriate prognosis and options for treatment.

Original languageEnglish (US)
Pages (from-to)81-88
Number of pages8
JournalHistopathology
Volume71
Issue number1
DOIs
StatePublished - Jul 1 2017

Fingerprint

Multiple Myeloma
Paraproteinemias
Plasmablastic Lymphoma
HIV
Data Mining
RNA Viruses
In Situ Hybridization
Glass

Keywords

  • CD117
  • KIT
  • myeloma
  • plasmablastic lymphoma
  • plasmablastic plasma cell myeloma

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology

Cite this

CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma. / Marks, Etan; Shi, Yang; Wang, Yanhua.

In: Histopathology, Vol. 71, No. 1, 01.07.2017, p. 81-88.

Research output: Contribution to journalArticle

@article{f442ef221e1c4fb99c2f686e3eab4c63,
title = "CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma",
abstract = "Aims: Plasmablastic plasma cell myeloma (PPCM) is a rare morphological presentation of multiple myeloma, and can resemble plasmablastic lymphoma (PBL), a human immunodeficiency virus (HIV)-related lymphoid neoplasm, morphologically and immunophenotypically. The aim of this study was to retrospectively search for factors that could help to differentiate these two entities. Methods and results: We used clinical looking glass, a data mining tool, to identify patients with a diagnosis of either PPCM or PBL with a CD117 test performed. We identified 27 cases from 16 patients in our institution with a diagnosis of either PPCM or PBL. There were 14 cases of PBL from eight patients and 13 cases of PPCM from eight patients. We found that six of eight patients with PPCM were positive for CD117, whereas no patients with PBL (0/8) showed positivity (P = 0.007 for patients). All (8/8) PPCM patients had a paraproteinaemia, whereas only two of eight PBL patients had a paraproteinaemia (P = 0.007). Lytic bone lesions were more indicative of a PPCM, with six of eight patients showing these lesions, and only one of eight PBL patients showing these lesions (P = 0.0406). HIV status was more likely to be positive in PBL patients, with six of seven patients showing positivity, and only one of five PPCM patients showing positivity (P = 0.072). Epstein–Barr virus-encoded RNA in-situ hybridization did not differentiate these two entities, with seven of eight PBL patients showing positivity, and two of five PPCM patients showing positivity (P = 0.2168). Conclusions: This study reveals that CD117 can be a useful marker to help differentiate PPCM from PBL and give the patient an appropriate prognosis and options for treatment.",
keywords = "CD117, KIT, myeloma, plasmablastic lymphoma, plasmablastic plasma cell myeloma",
author = "Etan Marks and Yang Shi and Yanhua Wang",
year = "2017",
month = "7",
day = "1",
doi = "10.1111/his.13196",
language = "English (US)",
volume = "71",
pages = "81--88",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - CD117 (KIT) is a useful marker in the diagnosis of plasmablastic plasma cell myeloma

AU - Marks, Etan

AU - Shi, Yang

AU - Wang, Yanhua

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Aims: Plasmablastic plasma cell myeloma (PPCM) is a rare morphological presentation of multiple myeloma, and can resemble plasmablastic lymphoma (PBL), a human immunodeficiency virus (HIV)-related lymphoid neoplasm, morphologically and immunophenotypically. The aim of this study was to retrospectively search for factors that could help to differentiate these two entities. Methods and results: We used clinical looking glass, a data mining tool, to identify patients with a diagnosis of either PPCM or PBL with a CD117 test performed. We identified 27 cases from 16 patients in our institution with a diagnosis of either PPCM or PBL. There were 14 cases of PBL from eight patients and 13 cases of PPCM from eight patients. We found that six of eight patients with PPCM were positive for CD117, whereas no patients with PBL (0/8) showed positivity (P = 0.007 for patients). All (8/8) PPCM patients had a paraproteinaemia, whereas only two of eight PBL patients had a paraproteinaemia (P = 0.007). Lytic bone lesions were more indicative of a PPCM, with six of eight patients showing these lesions, and only one of eight PBL patients showing these lesions (P = 0.0406). HIV status was more likely to be positive in PBL patients, with six of seven patients showing positivity, and only one of five PPCM patients showing positivity (P = 0.072). Epstein–Barr virus-encoded RNA in-situ hybridization did not differentiate these two entities, with seven of eight PBL patients showing positivity, and two of five PPCM patients showing positivity (P = 0.2168). Conclusions: This study reveals that CD117 can be a useful marker to help differentiate PPCM from PBL and give the patient an appropriate prognosis and options for treatment.

AB - Aims: Plasmablastic plasma cell myeloma (PPCM) is a rare morphological presentation of multiple myeloma, and can resemble plasmablastic lymphoma (PBL), a human immunodeficiency virus (HIV)-related lymphoid neoplasm, morphologically and immunophenotypically. The aim of this study was to retrospectively search for factors that could help to differentiate these two entities. Methods and results: We used clinical looking glass, a data mining tool, to identify patients with a diagnosis of either PPCM or PBL with a CD117 test performed. We identified 27 cases from 16 patients in our institution with a diagnosis of either PPCM or PBL. There were 14 cases of PBL from eight patients and 13 cases of PPCM from eight patients. We found that six of eight patients with PPCM were positive for CD117, whereas no patients with PBL (0/8) showed positivity (P = 0.007 for patients). All (8/8) PPCM patients had a paraproteinaemia, whereas only two of eight PBL patients had a paraproteinaemia (P = 0.007). Lytic bone lesions were more indicative of a PPCM, with six of eight patients showing these lesions, and only one of eight PBL patients showing these lesions (P = 0.0406). HIV status was more likely to be positive in PBL patients, with six of seven patients showing positivity, and only one of five PPCM patients showing positivity (P = 0.072). Epstein–Barr virus-encoded RNA in-situ hybridization did not differentiate these two entities, with seven of eight PBL patients showing positivity, and two of five PPCM patients showing positivity (P = 0.2168). Conclusions: This study reveals that CD117 can be a useful marker to help differentiate PPCM from PBL and give the patient an appropriate prognosis and options for treatment.

KW - CD117

KW - KIT

KW - myeloma

KW - plasmablastic lymphoma

KW - plasmablastic plasma cell myeloma

UR - http://www.scopus.com/inward/record.url?scp=85020429176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020429176&partnerID=8YFLogxK

U2 - 10.1111/his.13196

DO - 10.1111/his.13196

M3 - Article

VL - 71

SP - 81

EP - 88

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -